New quarterly report expected Apr 21, 2026. Report will refresh after results.
D
Quest Diagnostics Incorporated
DGX · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
The Lab Medicare Can't Kill and the Market Won't Love
The market is pricing Quest as a mature utility grinding through reimbursement headwinds — but the real question nobody is asking loudly enough is what happens to this company's volume and margin profile if multi-cancer early detection achieves broad CMS coverage and becomes the next mass-market blood draw flowing through the existing collection network.
Flowly Score
Apr 16 Close
+9%$191.46
Fair Value
$208.00
54
Averageat $191.46
Business Strength6/10
The scale moat and embedded physician workflows are genuine and took decades to build, but ROIC in the low double digits reflects a capital-intensive toll road that earns acceptable rather than exceptional returns — and the combined Chairman-CEO structure removes a key governance check on a management team whose compensation is quietly rising.
Financial Resilience6/10
Cash conversion quality is textbook excellent — operating cash flow runs well ahead of reported earnings with no accrual games — but the $6.9B debt stack sitting against minimal cash means any sustained FCF compression from reimbursement cuts lands directly on equity holders with no balance sheet cushion to absorb it.
Growth & Trajectory6/10
The 2025 recovery is real, not manufactured — organic volume, health plan network re-inclusions, and consumer testing inflecting past prior guidance thresholds all point the same direction — but the structural ceiling is set by Medicare reimbursement schedules and a purely domestic revenue base with no geographic escape valve.
Valuation6/10at $199.70
The DCF neutral scenario lands almost exactly at the current price, the FCF yield is respectable but not cheap, and the multiple is modestly above its five-year average on earnings — there is no meaningful margin of safety here, just a fair price for a fair business.
Risk5/10
PAMA-driven Medicare reimbursement cuts are a permanent, legislatively-imposed headwind that can't be negotiated away — and at current leverage levels, even modest sustained FCF compression has no buffer — while payer vertical integration remains the slow-motion existential scenario the market hasn't fully priced.
Quest is a textbook case of a business that is genuinely good but not genuinely cheap. The scale moat is real — no one is building a competing nationwide specimen logistics network from scratch — the cash conversion is excellent, and management has been disciplined rather than acquisitive for ego. But the current price reflects all of that: the DCF neutral case lands at essentially today's quote, the multiple is not stretched but is not a gift, and the FCF yield is the kind of number that makes this interesting rather than compelling. The investment case only works if you believe the current organic growth trajectory persists and one of the advanced diagnostics vectors — particularly oncology liquid biopsy — inflects from niche to mainstream. The trajectory over the next five years will be determined by two competing forces that operate on different timescales. In the near term, the Corewell partnership, health plan re-inclusions, and consumer testing at above-average margins are all real growth vectors that the market hasn't fully valued. The longer arc belongs to the question of whether earlier disease detection becomes a cultural norm reinforced by clinical guidelines and wearable data — if it does, Quest's collection infrastructure is the plumbing that routes that volume, and the addressable market expands faster than point-of-care devices can cannibalize the core. The single most specific risk is Medicare reimbursement compression via PAMA. This is not an abstract regulatory threat — it is a legislated mechanism that periodically resets what the government pays per test, anchors commercial payer negotiations downward, and is structurally impossible for Quest to price around. With $6.9B of debt in the capital structure, sustained FCF compression of even a few percentage points annually compounds quickly into a leverage problem, not just an earnings problem.